These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 5563487)

  • 21. Clinical evaluation of cyanate in sickle cell anemia.
    Harkness DR; Roth S
    Prog Hematol; 1975; 9():157-84. PubMed ID: 766071
    [No Abstract]   [Full Text] [Related]  

  • 22. Review of the development of cyanate as a drug in the treatment of sickle cell anemia.
    Cerami A
    Ann N Y Acad Sci; 1974 Nov; 241(0):538-44. PubMed ID: 4611307
    [No Abstract]   [Full Text] [Related]  

  • 23. Enhancement of filterability of sickle cells by cyanate: an effect independent of oxygen saturation.
    Wagner SM; Bishop J; Flanigan PW; Bromberg PA; Balcerzak SP
    J Lab Clin Med; 1975 Mar; 85(3):445-50. PubMed ID: 1117207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of cyanate on red blood cell sickling.
    Cerami A; Manning JM; Gillette PN; De Furia F; Miller D; Graziano JH; Peterson CM
    Fed Proc; 1973 Jun; 32(6):1668-72. PubMed ID: 4268029
    [No Abstract]   [Full Text] [Related]  

  • 25. Relationship between the oxygen affinity and in vitro sickling propensity of carbamylated sickle erythrocytes.
    Diederich D
    Biochem Biophys Res Commun; 1972 Feb; 46(3):1255-61. PubMed ID: 5012168
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of cyanate on sickling.
    May A; Bellingham AJ; Huehns ER; Beaven GH
    Lancet; 1972 Mar; 1(7752):658-61. PubMed ID: 4125163
    [No Abstract]   [Full Text] [Related]  

  • 27. Sickle cell anemia and dietary precursors of cyanate.
    Houston RG
    Am J Clin Nutr; 1973 Nov; 26(11):1261-4. PubMed ID: 4594066
    [No Abstract]   [Full Text] [Related]  

  • 28. Red cell survival of cyanate reacted sickle cells.
    Bellingham AJ; May A; Huehns ER
    Clin Sci; 1972 Apr; 42(4):21P. PubMed ID: 5020279
    [No Abstract]   [Full Text] [Related]  

  • 29. New treatments for sickle cell disease.
    Med Lett Drugs Ther; 1973 Feb; 15(4):17-9. PubMed ID: 4695516
    [No Abstract]   [Full Text] [Related]  

  • 30. Continuous extracorporeal chemotherapy of blood utilizing hemodialysis: potential for the treatment of sickle cell disease.
    Kjellstrand CM; Shideman JR; Eaton JW
    Trans Am Soc Artif Intern Organs; 1974; 20 B():574-8. PubMed ID: 4450307
    [No Abstract]   [Full Text] [Related]  

  • 31. Chemical and biological aspects of the inhibition of red blood cell sickling by cyanate.
    Manning JM; Cerami A; Gillette PN; De Furia FG; Miller DR
    Adv Exp Med Biol; 1972; 28():253-60. PubMed ID: 5085171
    [No Abstract]   [Full Text] [Related]  

  • 32. Editorial: Sickle cell disease.
    Pearson HA
    Yale J Biol Med; 1974 Mar; 47(1):2-4. PubMed ID: 4825086
    [No Abstract]   [Full Text] [Related]  

  • 33. Some comparative aspects of carbamylation of human blood and of hemoglobin with cyanate and carbamyl phosphate.
    Carreras-Barnes J; Diederich DA; Grisolia S
    Eur J Biochem; 1972 May; 27(1):103-8. PubMed ID: 5049047
    [No Abstract]   [Full Text] [Related]  

  • 34. Preliminary studies of continuous extracorporeal carbamylation in the treatment of sickle cell anemia.
    Balcerzak SP; Grever MR; Sing DE; Bishop JN; Segal ML
    J Lab Clin Med; 1982 Sep; 100(3):345-55. PubMed ID: 7108349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New Approaches to the therapy of sickle cell disease.
    Luskey KL; Schechter AN; Hercules JI
    Tex Rep Biol Med; 1980-1981; 40():305-12. PubMed ID: 6172868
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparative evaluation of fifteen anti-sickling agents.
    Chang H; Ewert SM; Bookchin RM; Nagel RL
    Blood; 1983 Apr; 61(4):693-704. PubMed ID: 6338971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of the blood concentrations of cyanate after intravenous administration to patients with sickle-cell disease.
    Nigen AM; Peterson CM; Gillette PN; Manning JM
    J Lab Clin Med; 1974 Jan; 83(1):139-46. PubMed ID: 4808651
    [No Abstract]   [Full Text] [Related]  

  • 38. Editorial: Optimal vs optional testing for sickle cell disease.
    Bemis EL
    JAMA; 1975 Nov; 234(8):855-6. PubMed ID: 1242480
    [No Abstract]   [Full Text] [Related]  

  • 39. An extracorporeal system that modifies hemoglobin in patients with sickle cell anemia.
    Babb AL; Scribner BH; Uvelli DA; Fry DL; Agodoa LC
    Artif Organs; 1979 Feb; 3(1):62-72. PubMed ID: 435126
    [No Abstract]   [Full Text] [Related]  

  • 40. Studies with intravenous sodium cyanate in patients with sickle cell anemia.
    Peterson CM; Lu YS; Herbert JT; Cerami A; Gillette PN
    J Pharmacol Exp Ther; 1974 Jun; 189(3):577-84. PubMed ID: 4602044
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.